证券代码：301580 证券简称：爱迪特 公告编号：2026-004 爱迪特（秦皇岛）科技股份有限公司 特别提示： 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2026 年 1 月 15 日在巨潮资讯网披露了《关于持股 5%以上股东减持股份预披露公告》（公告 编号：2026-001）（以下简称"本次减持计划"）。公司持股 5%以上股东苏州 君联欣康创业投资合伙企业（有限合伙）（以下简称"君联欣康"）以及康拓有 限公司（HEALTH ADVANCE LIMITED）（以下简称"HAL"）计划自上述公 告披露之日起 15 个交易日之后 3 个月内通过集中竞价或大宗交易方式减持公司 股份，减持数量合计不超过 3,196,930 股（占公司总股本的 3.0000%）。其中， 通过集中竞价方式减持不超过 1,065,640 股（占公司总股本的 1.0000%），通过 大宗交易方式减持不超过 2,131,290 股（占公司总股本的 2.0000%）。 近日，公司收到股东君联欣康和 HAL 出具的告知函，2026 年 2 月 10 日至 2026 年 2 月 12 日期间，君联欣康和 HAL 两家通过大宗交易和 ...

Core Viewpoint - Aidi Te (301580.SZ) is progressing with the construction of its dental industrial park as planned, expected to commence production in the second half of this year, which will significantly enhance the company's overall capacity [1] Group 1 - The construction of the dental industrial park is on schedule and will begin production in the latter half of the year [1] - The company plans to release the new park's capacity in phases, aligning it with market demand and order forecasts to ensure efficient utilization of the new capacity [1] - The strategy aims to match the pace of capacity release with the growth rate of orders, ensuring orderly digestion and effective use of the increased capacity [1]

格隆汇2月12日丨爱迪特(301580.SZ)披露投资者关系活动记录表显示，公司定位是面向义齿加工厂和口 腔医院/诊所客户，提供口腔材料、设备以及完整的数字化解决方案，公司并不直接参与下游产业链的 运营和生产。公司持续通过技术输出与产能赋能，为下游合作方输出全流程数字化解决方案。 ...

Group 1: Capacity Expansion and Production Plans - The construction of the dental industry park is progressing as planned, expected to commence production in the second half of 2026, which will significantly enhance overall capacity [2] - The company plans to release new park capacity in phases, aligning with market demand and order forecasts to ensure efficient utilization of new capacity [2] Group 2: Market Positioning and Business Strategy - The company focuses on providing dental materials, equipment, and complete digital solutions to dental labs and clinics, without directly engaging in downstream operations [2] - Continuous technical output and capacity empowerment are employed to provide comprehensive digital solutions to downstream partners [2] Group 3: Overseas Market Growth Factors - The overseas market growth is driven by three main factors: enhanced product competitiveness, solid customer relationships in Europe and the US, and effective supply chain and service advantages [3] - The company has deepened cooperation with key clients, leading to increased customer coverage and penetration rates [3] Group 4: Investment in Raw Material Supply - The investment in Jingdezhen Wanwei Powder Co., Ltd. aims to stabilize the supply chain and enhance collaborative research and development for the specific requirements of zirconia ceramic block products [4] Group 5: Profitability in Overseas Markets - The higher gross margin in overseas markets compared to domestic markets is attributed to the product structure differences and benefits from export tax rebates, which lower overall export costs [5]

Core Viewpoint - The AI medical sector experienced a decline of 0.66% on February 11, with QianYuan Pharmaceutical leading the drop. The Shanghai Composite Index rose by 0.09%, while the Shenzhen Component Index fell by 0.35% [1]. Group 1: Market Performance - The closing price of QianYuan Pharmaceutical was 11.44, down by 4.67%, with a trading volume of 209,800 shares and a transaction value of 243 million [2]. - The AI medical sector saw a net outflow of 1.345 billion from major funds, while retail investors contributed a net inflow of 1.14 billion [2][3]. Group 2: Individual Stock Performance - YoukeDe (688158) closed at 37.54, up by 5.12%, with a trading volume of 631,000 shares and a transaction value of 2.36 billion [1]. - AidiTe (301580) closed at 55.18, up by 4.63%, with a trading volume of 46,100 shares and a transaction value of 251 million [1]. - SanNuo Biology (300298) closed at 18.54, up by 2.71%, with a trading volume of 105,200 shares and a transaction value of 194 million [1]. - The top decliners included QianYuan Pharmaceutical (300254) and KaiPu Biology (300639), with declines of 4.67% and 4.23%, respectively [2].

Core Viewpoint - On February 11, a block trade of 400,000 shares of Aidi Te was executed at a price of 49.66 yuan, representing a discount of 10% compared to the market closing price of 55.18 yuan, with a total transaction value of 19.864 million yuan, accounting for 7.34% of the total trading volume that day [1]. Group 1: Transaction Details - The block trade involved a total of 400,000 shares, with a transaction value of 19.864 million yuan [1]. - The transaction price was set at 49.66 yuan per share, which is 10% lower than the market closing price of 55.18 yuan [1]. - The total trading volume for the day was significantly impacted, with the block trade accounting for 7.34% of the total trading volume [1]. Group 2: Breakdown of Transactions - Multiple transactions were recorded on February 11, with various volumes and values, all at the same price of 49.66 yuan per share [2]. - The largest single transaction recorded was for 100,000 shares, amounting to 4.966 million yuan [2]. - Other transactions included volumes of 57,000 shares (2.8306 million yuan), 48,000 shares (2.3837 million yuan), and 47,000 shares (2.3340 million yuan), all executed at the same price [2].

Core Viewpoint - The company is making significant progress in its 3D printing business, which is expected to become a new core performance driver with notable advantages [1] Group 1: 3D Printing Business Development - The company's 3D printing business is advancing well and is anticipated to be a new core performance engine [1] - The EZprint-P1 printer offers high-speed printing capabilities, completing a half-arch bridge in just 20 minutes, significantly enhancing industry production efficiency [1] - The printing materials used have a solid content of 53% and have received FDA certification, with domestic and EU certifications expected to be finalized soon [1] Group 2: Market Potential and Applications - The company believes the dental 3D printing market has vast development and growth potential [1] - The maturity of 3D printing products and technologies is continuously improving, with applications expanding into various fields such as implants and orthodontics [1] - Relevant clinical solutions have completed market validation, supporting the company's strategic direction [1] Group 3: Competitive Advantage - The company leverages a full-chain layout advantage in materials, equipment, and solutions to deepen its focus on the 3D printing business [1]

证券代码：301580 证券简称：爱迪特 公告编号：2026-002 爱迪特（秦皇岛）科技股份有限公司 关于公司向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 三、备查文件 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）于 2026 年 2 月 10 日召开了第四届董事会第三次会议，会议审议通过《关于公司向银行申请 综合授信额度的议案》，同意公司及子公司向银行申请总额不超过人民币 9 亿 元（含本数）的综合授信额度，现将议案有关情况公告如下： 1.《爱迪特（秦皇岛）科技股份有限公司第四届董事会第三次会议决议》 特此公告。 一、基本情况 爱迪特（秦皇岛）科技股份有限公司董事会 2026 年 2 月 10 日 为满足公司 2026 年度日常生产经营和业务发展的资金需求，公司及子公司 拟向银行申请合计不超过人民币 9 亿元（含本数）的综合授信额度。授信业务 种类包括但不限于非流动资金贷款、流动资金贷款、信用证、银行票据、外汇 衍生品业务等，上述授信额度仅为公司拟申请的授信额度，具体授信金额需根 据公司实际资金需求，以与银行签署的相 ...

证券代码：301580 证券简称：爱迪特 公告编号：2026-003 爱迪特（秦皇岛）科技股份有限公司 第四届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 爱迪特（秦皇岛）科技股份有限公司（以下简称"公司"）第四届董事会 第三次会议于 2026 年 2 月 10 日在秦皇岛市经济技术开发区都山路 9 号公司会 议室以现场与通讯方式相结合的方式召开。会议通知于 2026 年 2 月 4 日以电子 邮件的方式向全体董事和相关与会人员发出。会议由李洪文先生召集并主持。 会议应出席董事 9 人，实际出席董事 9 人，董事李洪文先生、李斌先生、汪剑 飞先生、王雪松女士、Zhang Yu 先生、傅穹先生、贾国军先生、冯海兰女士以 通讯方式出席会议。公司高级管理人员列席会议。会议召集及召开程序符合 《公司法》等法律法规、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 （一）审议通过《关于公司向银行申请综合授信额度的议案》 经审议，为满足公司 2026 年度日常生产经营和业务发展的资金需求，董事 会同意公司及子 ...

Core Viewpoint - The company anticipates that its overall revenue growth pace in 2025 will be consistent with the first three quarters, with profit growth outpacing revenue growth [1] Group 1: Revenue and Profit Growth - The company is experiencing good growth in profitability, with profit growth rate exceeding revenue growth rate [1] - The proportion of overseas business revenue has increased compared to the previous year, becoming a significant support for revenue growth and diversifying the revenue structure [1] Group 2: Global Market Expansion - The company is continuously advancing its global market layout, which helps to mitigate operational risks [1] Group 3: Product Structure Optimization - The company has made positive progress in optimizing its product structure, leading to steady improvement in overall operational quality [1] Group 4: Core Business Focus - In 2025, the company will continue to focus on core materials such as dental zirconia blocks as its business foundation [1] Group 5: Digital Equipment Development - The dental digital equipment business has shown significant development, with multiple devices receiving high market recognition, establishing competitive barriers in product strength, channel reuse, and supply chain [1] - The company plans to increase investment and development in its equipment business [1] Group 6: New Business Breakthroughs - The new business segments have achieved multiple breakthroughs, with rapid advancement in digital full-arch denture business, laying the foundation for large-scale promotion [1] - The implant and 3D printing businesses have also made breakthroughs in both product and market aspects [1] Group 7: Future Reporting - Specific operational data for the fourth quarter and the entire year will be disclosed in the company's upcoming annual report [1]